De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR.
about
Interleukin-2 receptor signaling: at the interface between tolerance and immunityBalancing Inflammation: The Link between Th17 and Regulatory T CellsImmunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantationIntegrating canonical and metabolic signalling programmes in the regulation of T cell responsesFOXO transcription factors throughout T cell biologySecretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cellsTGF-beta/atRA-induced Tregs express a selected set of microRNAs involved in the repression of transcripts related to Th17 differentiationPharmacotherapy for uveitis: current management and emerging therapy.Induction of T cell anergy: integration of environmental cues and infectious tolerance.Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection.Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study.Kinase suppressor of Ras 1 is not required for the generation of regulatory and memory T cells.Regulating functional cell fates in CD8 T cells.The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.mTOR signaling, Tregs and immune modulation.Negative regulation of mTOR activation by diacylglycerol kinases.mTOR Links Environmental Signals to T Cell Fate Decisions.Cellular size as a means of tracking mTOR activity and cell fate of CD4+ T cells upon antigen recognitionRapamycin attenuates airway hyperreactivity, goblet cells, and IgE in experimental allergic asthma.TOR in the immune system.Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.Regulation and function of mTOR signalling in T cell fate decisions.All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells.High TCR stimuli prevent induced regulatory T cell differentiation in a NF-κB-dependent mannerThe influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells.Progesterone suppresses the mTOR pathway and promotes generation of induced regulatory T cells with increased stability.Activated mammalian target of rapamycin is associated with T regulatory cell insufficiency in nasal polyps.Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways.MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway.mTOR and metabolic pathways in T cell quiescence and functional activation.mTOR: taking cues from the immune microenvironment.Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells.The mammalian target of rapamycin: linking T cell differentiation, function, and metabolismSmall-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.Regulation of immune responses by mTOR.Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells.mTOR, metabolism, and the regulation of T-cell differentiation and function.Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity.
P2860
Q24599806-0A282D9D-A8AB-4808-9F62-A08422B6716AQ26740440-3450EADF-C091-4B9F-8763-8C7A18D233B8Q26751433-2105F7FA-7A46-47A6-B754-A1B74E31B823Q26851446-62DE7BA4-6779-4B27-92DA-8F9493469E49Q26853741-FF61F18F-8B87-49DB-81E2-9EEE40511426Q28512213-BA4CE267-3ACA-41E8-85EB-96A0F3FE10B7Q33804010-4CF362CF-3751-4180-8EE7-EF9A775E2F2FQ34274075-4676D57D-6C58-494E-A7DC-BD66ABD42137Q34310174-C9AF511B-11B5-4AD2-9468-B6C0DC140105Q34412837-8BF6E610-A55F-47A1-8B8A-EBF5391B3E44Q34437449-43A46AC7-C92E-476E-859D-30D6849A5D8DQ34449084-ED60B6E3-4DC7-4364-95A5-5899A89A6424Q34595268-86969050-7338-47EF-AE89-D6C8F748FC05Q34613183-67FD986E-6660-4066-8833-2E10A87B1A63Q34801853-F96C546C-AF76-4C9E-BB47-079DE52BD9CCQ34919712-D4CB7256-32BE-453B-990E-42699ED1D71CQ34924347-474C86E7-681F-4574-BEE9-F1D03D68AD71Q34986648-2FA90A04-FEB7-4274-A1AC-AE297AF1DD19Q35304382-1ACDA32E-415B-4E40-B6F7-271A0D81C4C8Q35566801-9FCDB938-23BE-4DD3-ACB8-1A6BC449ED2DQ35621941-22F1EEB7-5232-40D8-B829-3862BE371166Q35743830-8EF5001F-852E-48A7-B48F-466C1967E9D0Q35836112-6297231F-577D-44A1-85B8-7953ABFB4C64Q36157753-DBA80ACE-556A-485A-A91C-874A5C90512FQ36303948-C2AE6119-C26F-40E1-867F-B871899602E3Q36530189-5DB6AA09-02E3-4A30-B3F7-562F7F801F1FQ36882243-E1532316-3C9D-4F05-9E08-7A14062C9B29Q36890286-0825F41D-79ED-46F8-A1DF-949721C8CCE1Q37118916-45FEA22C-DCB4-44D4-9111-9F4FF7A3EAE2Q37277855-951E8857-6AD7-4AC2-817E-F7B07856071AQ37293983-88C8B890-6C5A-4B30-808D-E44743CADD0CQ37373850-16964D22-E8A1-4741-B185-B605740B0639Q37552045-846719CC-61BA-4335-8F75-940700A43033Q37630237-AB37BBB1-0848-4BFD-8B02-A83BAA4762F6Q37792556-18021A5E-0FB5-4D42-AC89-1105752A9DF4Q37842326-41884364-4E30-4CBC-9376-C55E15EA852EQ37963950-B84FACB2-D123-4260-A2E8-C174D533C61FQ38007403-B00D595E-D0EE-45A6-AD0B-1C7559C2FE45Q38034265-A70152A2-6E0F-436C-A540-F6A4B0574D1EQ38034270-4F474E67-5571-43D0-8F55-F3FA5B252928
P2860
De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
De novo induction of antigen-s ...... companied by blockade of mTOR.
@en
De novo induction of antigen-s ...... companied by blockade of mTOR.
@nl
type
label
De novo induction of antigen-s ...... companied by blockade of mTOR.
@en
De novo induction of antigen-s ...... companied by blockade of mTOR.
@nl
prefLabel
De novo induction of antigen-s ...... companied by blockade of mTOR.
@en
De novo induction of antigen-s ...... companied by blockade of mTOR.
@nl
P2093
P2860
P356
P1476
De novo induction of antigen-s ...... companied by blockade of mTOR.
@en
P2093
Joanne M Fraser
Johnthomas Kang
Stephen J Huddleston
P2860
P304
P356
10.1189/JLB.1207851
P577
2008-02-12T00:00:00Z